AAP
CTKB icon

Arax Advisory Partners’s Cytek Biosciences CTKB Stock Holding History

Arax Advisory Partners’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.67K Buy
221
+209
+1,742% +$987 ﹤0.01% 3154
2025
Q4 		$61 Sell
12
-30,247
-100% -$140K ﹤0.01% 3891
2025
Q3 		$105K Buy
+30,259
New +$114K ﹤0.01% 1522
2025
Q1 		– Sell
-187
Closed -$1.21K – 2752
2024
Q4 		$1.21K Buy
+187
New +$1.11K ﹤0.01% 2127

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arax Advisory Partners's CTKB Position: Q1 2026 in Review

Arax Advisory Partners increased its Cytek Biosciences (CTKB) stake by 1,742% in Q1 2026, buying an estimated $987 and bringing the position to 221 shares worth $1.67K. The position accounts for ﹤0.01% of the portfolio, ranked #3154.

Arax Advisory Partners first reported a position in CTKB in Q4 2024 and has held it in 4 quarters since. The position peaked at $105K in Q3 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Arax Advisory Partners held 221 shares of Cytek Biosciences worth $1.67K as of Q1 2026.
  • Arax Advisory Partners bought 209 Cytek Biosciences shares in Q1 2026, an estimated $987.
  • Cytek Biosciences made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3154 holding.
  • Arax Advisory Partners first reported a position in Cytek Biosciences in Q4 2024 and has held it in 4 quarters since.
  • Arax Advisory Partners's Cytek Biosciences position peaked at $105K in Q3 2025.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.